Celiac Disease – Pipeline Review, H2 2018 – ResearchAndMarkets.com

Disease – Pipeline Review, H2 2018”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Celiac Disease – Pipeline Review, H2 2018, provides comprehensive
information on the therapeutics under development for Celiac Disease
(Gastrointestinal), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type. The guide covers the descriptive pharmacological action
of the therapeutics, its complete research and development history and
latest news and press releases.

The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key
players involved in therapeutic development for Celiac Disease and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Phase II, Phase I, Preclinical
and Discovery stages are 6, 3, 9 and 5 respectively. Similarly, the
Universities portfolio in Phase I stages comprises 1 molecules,

Celiac Disease (Gastrointestinal) pipeline guide helps in identifying
and tracking emerging players in the market and their portfolios,
enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage.

Featured News & Press Releases

  • ImmusanT CEO Leslie Williams to Discuss Immunology of Celiac Disease
    at 2018 BIO International Convention
  • ImmusanT Expands Management Team to Strengthen Financial Operations
    and Accelerate Clinical Development
  • Celiac Disease KOL and Management Meetings around the Digestive
    Disease Week (DDW) conference on Monday, June 4, 2018, in Washington,
  • ImmusanT Welcomes Ken Truitt as Chief Medical Officer
  • ImmusanT Welcomes Ken Truitt, M.D. as Chief Medical Officer
  • Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for
    the Digestive Disease Week 2018 Conference
  • Cour Pharmaceuticals Receives FDA Fast Track Designation For TIMP-GLIA
  • ImmusanT Provides Year-End Update and Outlines Goals for 2018
  • ImmusanT Data Shows Up-Dosing Substantially Increases Nexvax2 Dose
    Levels That Are Safe and Tolerable, Further Supports Phase II Studies
  • ImmusanT Presents Clinical Data Supporting Improved Dosing Strategy
    for Nexvax2 and Explaining Early Gluten-Related Clinical Effects in
    Celiac Disease
  • ImmusanT Announces Acceptance of Late Breaking Celiac Interleukin Data
    at United European Gastroenterology Week
  • ImmusanT to Present New Nexvax2 Dosing Data at United European
    Gastroenterology Week
  • Bioniz Therapeutics Presents Data Demonstrating the Synergistic
    Effects of Cytokines IL-15 and IL-21 in Celiac Disease Pathogenesis
  • ImmusanT Presents Data from Multiple Studies Supporting Continued
    Development of Nexvax
  • ImmunogenX Announces Publication of New Latiglutenase Analyses in
    Digestive Disease & Science

Companies Featured

  • Amgen Inc.
  • Calypso Biotech SA
  • IB Pharmaceuticals Inc.
  • ImmusanT Inc.
  • Intrexon Corp.
  • Takeda Pharmaceutical Co Ltd.
  • Topas Therapeutics GmbH
  • Zedira GmbH

Key Topics Covered

1. Introduction

2. Report Coverage

3. Celiac Disease – Overview

4. Celiac Disease – Therapeutics Development

5. Pipeline Overview

6. Pipeline by Companies

7. Pipeline by Universities/Institutes

8. Products under Development by Companies

9. Products under Development by Universities/Institutes

10. Celiac Disease – Therapeutics Assessment

11. Celiac Disease – Companies Involved in Therapeutics Development

12. Celiac Disease – Drug Profiles

13. Celiac Disease – Dormant Projects

14. Celiac Disease – Product Development Milestones

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fzxrht/celiac_disease?w=4.


Laura Wood, Senior Manager
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Immune
Disorders Drugs
, Gastrointestinal